We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Change in Serum Bilirubin Level Predicts Incident Metabolic Syndrome

By LabMedica International staff writers
Posted on 21 Dec 2016
Metabolic syndrome (MetS) is a constellation of interlinked metabolic conditions that seem to accelerate the development of cardiovascular disease. Chronic inflammation, oxidative stress, and insulin resistance all play important roles in the initiation and advancement of MetS.

Serum bilirubin level was negatively associated with the prevalence of MetS in previous cross-sectional studies; however, bilirubin variance preceding the development of MetS has yet to be investigated. An inverse association between mean bilirubin concentrations and the number of metabolic syndrome components in a population with atherogenic dyslipidemia has been reported.

Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) conducted a retrospective longitudinal study of subjects who had undergone at least four yearly health check-ups between 2006 and 2012. Of 24,185 total individuals who received annual check-ups, 11,613 non-MetS participants with a baseline bilirubin level not exceeding 34.2 μmol/L were enrolled. Venous blood samples were obtained after an overnight fast and measurements included serum bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), fasting plasma glucose, plasma insulin, triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum uric acid, and creatinine.

Serum bilirubin concentrations were measured using the diazonium salt/diazonium ion with blank method on a Hitachi-7600, Modular DP-110 autoanalyzer (Hitachi, Tokyo, Japan). Plasma glucose levels were determined using the hexokinase method on an Advia 1650 automated chemistry analyzer, and plasma insulin values were derived using an immunoradiometric assay. Fasting HDL-C, LDL-C, and TG were measured using the enzymatic colorimetric method with a Modular D2400.

The scientists found that during 55,407 person-years of follow-up, 2,439 cases of incident MetS developed (21.0%). There was an increased risk for incident MetS that was observed in higher percent change in bilirubin quartiles, with hazard ratios of 2.415 in men and 2.156 in women in the fourth quartile, compared to the lowest quartile, after adjusting for various variables. The hazard ratios per one standard deviation increase in percent change in bilirubin as a continuous variable were 1.277 in men and 1.366 in women.

The authors concluded that an increase in bilirubin concentration, defined as PCB, was positively associated with incident MetS in a healthy Korean population, indicating that bilirubin increase might precede the development of MetS. Positive levels of PCB may reflect an increase in oxidative stress preceding new-onset MetS. The study was published on December 9, 2016, in the journal Public Library of Science ONE.

Related Links:
Sungkyunkwan University School of Medicine
Hitachi


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Silver Member
ACTH Assay
ACTH ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.